Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease - PubMed (original) (raw)
. 2010 Mar;332(3):1064-71.
doi: 10.1124/jpet.109.162115. Epub 2009 Nov 25.
Affiliations
- PMID: 19940105
- DOI: 10.1124/jpet.109.162115
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease
B Greco et al. J Pharmacol Exp Ther. 2010 Mar.
Abstract
Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD). Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known. The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD. Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats. AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats. In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats. In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice. Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD. Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity. Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies.
Similar articles
- Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.
Li X, Xi ZX, Markou A. Li X, et al. Neuropharmacology. 2013 Mar;66:12-23. doi: 10.1016/j.neuropharm.2012.04.010. Epub 2012 Apr 21. Neuropharmacology. 2013. PMID: 22546614 Free PMC article. Review. - Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W. Dekundy A, et al. Brain Res Bull. 2006 Apr 14;69(3):318-26. doi: 10.1016/j.brainresbull.2005.12.009. Epub 2006 Jan 25. Brain Res Bull. 2006. PMID: 16564428 - Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission.
Stachowicz K, Brañski P, Kłak K, van der Putten H, Cryan JF, Flor PJ, Andrzej P. Stachowicz K, et al. Behav Pharmacol. 2008 Sep;19(5-6):597-603. doi: 10.1097/FBP.0b013e32830cd839. Behav Pharmacol. 2008. PMID: 18690114 - Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T. Löschmann PA, et al. Synapse. 1997 Aug;26(4):381-91. doi: 10.1002/(SICI)1098-2396(199708)26:4<381::AID-SYN6>3.0.CO;2-2. Synapse. 1997. PMID: 9215597 - Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, Bernardi G, Calabresi P, Pisani A. Bonsi P, et al. Amino Acids. 2007 Feb;32(2):189-95. doi: 10.1007/s00726-006-0320-3. Epub 2006 May 22. Amino Acids. 2007. PMID: 16715415 Review.
Cited by
- Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.
Li X, Xi ZX, Markou A. Li X, et al. Neuropharmacology. 2013 Mar;66:12-23. doi: 10.1016/j.neuropharm.2012.04.010. Epub 2012 Apr 21. Neuropharmacology. 2013. PMID: 22546614 Free PMC article. Review. - Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.
Fabbrini A, Guerra A. Fabbrini A, et al. J Exp Pharmacol. 2021 Apr 29;13:469-485. doi: 10.2147/JEP.S265282. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33953618 Free PMC article. Review. - Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Broadstock M, Austin PJ, Betts MJ, Duty S. Broadstock M, et al. Br J Pharmacol. 2012 Feb;165(4b):1034-45. doi: 10.1111/j.1476-5381.2011.01515.x. Br J Pharmacol. 2012. PMID: 21627638 Free PMC article. - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Therapeutic potential of metabotropic glutamate receptor modulators.
Hovelsø N, Sotty F, Montezinho LP, Pinheiro PS, Herrik KF, Mørk A. Hovelsø N, et al. Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805. Curr Neuropharmacol. 2012. PMID: 22942876 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources